Pharmaceuticals News

Oslo, 17 August 2026: The Board of Directors of Zelluna ASA (the “Company”) hereby calls for an Extraordinary General Meeting to be held on 9 September 2026 at 13:00 CEST, regarding election of a new...

Oslo, 17 august 2026: Styret i Zelluna ASA («Selskapet») innkaller herved til ekstraordinær generalforsamling som avholdes 9. september 2026 kl 13:00  CEST, vedrørende valg av nytt styremedlem til...

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL SETTLEMENT AND DELIVERY OF SECURITIES ISSUED AS PART OF ITS €14.2 MILLION PRIVATE PLACEMENT ANNOUNCED ON AUGUST 10, 2026 Paris, August 17, 2026,...

COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES DU REGLEMENT-LIVRAISON DES TITRES EMIS DANS LE CADRE DE SON PLACEMENT PRIVE DE 14,2 MILLIONS D’EUROS ANNONCE LE 10 AOUT 2026 Paris, 17 août 2026,...

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011)Patient improvements observed early and sustained...

NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed...

— First global Phase III trial to show significant progression-free and overall survival benefits in this setting — — SAFFRON trial results reinforce TAGRISSO® as the backbone therapy across EGFRm...

Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product salesQUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured TORONTO,...

ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy AACR...

WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with...